Enovis Co. (NYSE:ENOV) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP cut its holdings in Enovis Co. (NYSE:ENOV) by 1.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,154,725 shares of the company’s stock after selling 40,007 shares during the period. Dimensional Fund Advisors LP owned 5.75% of Enovis worth $142,593,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Fidelis Capital Partners LLC purchased a new stake in Enovis in the first quarter valued at approximately $34,000. Principal Securities Inc. purchased a new stake in Enovis in the fourth quarter valued at approximately $41,000. Ridgewood Investments LLC purchased a new stake in Enovis in the second quarter valued at approximately $44,000. Innealta Capital LLC purchased a new stake in Enovis in the second quarter valued at approximately $65,000. Finally, GAMMA Investing LLC raised its position in Enovis by 19.9% in the first quarter. GAMMA Investing LLC now owns 1,085 shares of the company’s stock valued at $68,000 after purchasing an additional 180 shares during the period. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on ENOV shares. Evercore ISI cut their target price on Enovis from $70.00 to $62.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. JPMorgan Chase & Co. cut their price objective on Enovis from $53.00 to $50.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. Finally, Needham & Company LLC cut their price objective on Enovis from $82.00 to $65.00 and set a “buy” rating on the stock in a research report on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $69.13.

Enovis Stock Down 3.0 %

Enovis stock opened at $43.67 on Friday. Enovis Co. has a twelve month low of $39.98 and a twelve month high of $65.03. The stock’s fifty day simple moving average is $44.73 and its 200-day simple moving average is $49.97. The company has a current ratio of 2.26, a quick ratio of 1.08 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $2.40 billion, a P/E ratio of -29.11 and a beta of 1.92.

Enovis (NYSE:ENOV) last posted its earnings results on Wednesday, August 7th. The company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.59 by $0.03. The firm had revenue of $525.20 million for the quarter, compared to analyst estimates of $525.99 million. Enovis had a positive return on equity of 4.06% and a negative net margin of 4.73%. Enovis’s revenue for the quarter was up 22.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.61 earnings per share. As a group, equities analysts expect that Enovis Co. will post 2.7 earnings per share for the current fiscal year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.